New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 8, 2014
10:25 EDTDRRX, DRRX, PCRX, PCRXSummer Street's chief scientific officer holds analyst/industry conference call
Chief Scientific Officer Classen discusses Durect's (DRRX) Posidur for post-operative pain, its safety and whether it could be disruptive to Pacira Pharmaceuticals (PCRX) on an Analyst/Industry conference call to be held on January 8 at 11 am.
News For DRRX;PCRX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
October 30, 2014
13:12 EDTPCRXPacira weakness a buying opportunity, says Brean Capital
Brean Capital believes the weakness in shares of Pacira following its Q3 report is a buying opportunity, noting that the company hit the consensus for revenue despite a lower number of orthopedic surgeries, which the firm views as seasonally impacted. Brean also noted Pacira said it has seen no change in surgeons’ perception of Exparel following the FDA warning letter it received in September. The firm maintains its Buy rating and $111 price target on the stock.
10:55 EDTPCRXPacira shares defended at Wedbush
Subscribe for More Information
09:14 EDTPCRXOn The Fly: Pre-market Movers
UP AFTER EARNINGS: Visa (V), up 4%... MasterCard (MA), up 2.5%... Alcatel-Lucent (ALU), up 12.5%... TASER (TASR), up 4%... JDSU (JDSU), up 3.8%... Radian Group (RDN), up 9%... DreamWorks Animation (DWA), up 1.7%... Take-Two (TTWO), up 7.7%. ALSO HIGHER: Grand Canyon (LOPE), up 10.5%, upgraded at Piper Jaffray after the company formed a committee to explore conversion to a nonprofit entity... Walter Energy (WLT), up 6.8% after lowering FY14 capital expenditures view, reporting lower than expected losses... Novavax (NVAX), up 7% after getting fast track designation for H7N9 VLP. DOWN AFTER EARNINGS: Glu Mobile (GLUU), down 16.6%... Alliance Fiber Optic (AFOP), down 18.4%... Pacira (PCRX), down 6.4%. ALSO LOWER: Sturm, Ruger (RGR), down 10% following Q3 results, cutting Q3 dividend. Peer gunmaker Smith & Wesson (SWHC) also down 3.7% after Ruger's report... Western Gas Partners (WES), down 4.4% after its 7.5M common units spot secondary priced at $70.85... ACCO Brands (ACCO), down 1.1%, downgraded at KeyBanc following the company's Q3 results... Fiat Chrysler (FCAU), down 1.1% after reported to be recalling over 300K Ram trucks due to fire concern... Inogen (INGN), down 2.3% after 2.1M share secondary offering of common stock priced at $21.50.
06:32 EDTPCRXPacira reports Q3 Exparel net product sales up 12% to $50.2M
Subscribe for More Information
06:31 EDTPCRXPacira reports Q3 non-GAAP EPS 16c, consensus 10c
Subscribe for More Information
October 28, 2014
07:35 EDTDRRXDURECT price target liowered to $1.50 from $2.50 at Stifel
Subscribe for More Information
October 27, 2014
16:36 EDTDRRXOn The Fly: Closing Wrap
Subscribe for More Information
16:03 EDTPCRXPacira EXPAREL use leads to significant reduction in opioid adverse events
Pacira Pharmaceuticals announced results of an independent, physician-initiated study that reinforce the positive impact of an EXPAREL-based pain management regimen on reducing postsurgical complications associated with opioid use. The data, presented at the American College of Surgeons, or ACS, Clinical Congress, found that patients treated with EXPAREL experienced statistically significantly lower rates of urinary retention, respiratory depression and fall risk compared to their counterparts who received the previous standard of care, or SOC. The ACS Clinical Congress is being held October 26-30 at the Moscone Center in San Francisco. The study evaluated 82 patients undergoing open ventral hernia repair or laparoscopic colon resection, all of whom were treated by Dr. Redan. Thirty-seven patients received the SOC: intravenous hydromorphone or morphine with or without epidurals and/or IV acetaminophen. The other 45 patients received infiltration with EXPAREL in addition to the SOC. of EXPAREL resulted in a statistically significant reduction (P<0.001) in the amount of patients classified as being “high-risk” for falls (8.4% in the EXPAREL group vs 16% in the SOC group) and an increase in patients classified as being “low-risk” for falls (48.7% in the EXPAREL vs 37.6% in the SOC group), according to the Morse Fall Scale designed to predict falls, and assess and address risk factors contributing to fall risk.
08:15 EDTDRRXPain Therapeutics to regain full rights to REMOXY
Subscribe for More Information
08:08 EDTDRRXDURECT reports Pfizer to discontinue agreement with Pain Therapeutics
DURECT (DRRX) reported today that Pfizer (PFE) announced that it has notified Pain Therapeutics (PTIE) that Pfizer has decided to discontinue its agreement to develop and commercialize REMOXY Extended-Release Capsules CII, an investigational extended-release oral formulation of oxycodone. Pfizer will return all rights, including responsibility for regulatory activities, to Pain Therapeutics. As a result, Pain Therapeutics has the rights to develop and commercialize REMOXY on its own or with an alternative licensee. Pain Therapeutics had the rights to develop and commercialize this product candidate under a license from DURECT.
08:00 EDTDRRXDURECT trading halted, pending news
07:23 EDTPCRXAmerican College of Surgeons holds a conference
Subscribe for More Information
October 20, 2014
07:12 EDTPCRXCongress of Neurological Surgeons to hold annual meeting
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use